SBFM SBFM
Company Profile ↓Company Overview
SBFM (SBFM) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 247.7% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $36.31M (+4.1% YoY); net profit $-5.98M.
- Trailing 12 Months Year-on-year growth — revenue +4.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 247.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 247.73% |
| 1 Year: | 4.11% |
Stock Price Performance
| 1 Year: | -90.89% |
| 6 Months: | -89.19% |
| 3 Months: | -87.33% |
| 1 Month: | -36.06% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)29.67 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 247.7% over 5 years.
CONS
- Trading 94.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 91.17K | 0 | 0 | 206 | 3.03K | 7.33K | 11.10K | 15.14K | 17.15K | 40.06K | 52.87K | 50.38K | 122.64K | 150.31K | 132.81K | 4.89M | 5.56M | 5.96M | 7.54M | 9.30M | 8.44M | 8.90M | 9.41M | 9.42M | 8.09M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | -9.65K | 0 | 0 | 94 | 1.57K | 2.03K | 7.22K | 9.98K | 10.81K | 21.54K | 34.36K | 30.87K | 62.80K | 75.62K | 67.03K | 1.83M | 1.95M | 1.99M | 2.35M | 2.36M | 2.87M | 2.73M | 3.42M | 3.07M | 2.18M |
| Operating Income | -922.89K | -152.59K | -177.68K | -405.87K | -765.51K | -277.43K | -124.83K | -368.16K | -113.05K | -69.68K | -471.31K | -116.02K | -108.99K | -472.22K | -113.81K | -166.70K | -580.51K | -288.82K | -122.21K | -66.20K | -202.64K | -37.70K | -128.57K | -67.29K | -1.28M | -388.60K | -496.26K | -1.22M | -695.80K | -1.72M | -1.83M | -1.01M | -779.47K | -1.35M | -1.27M | -1.11M | -1.30M | -2.05M | -1.09M | -1.40M |
| Net Income | -1.48M | -152.97K | -178.06K | -501.25K | -765.51K | -280.85K | -294.37K | -517.51K | -202.81K | -305.29K | -481.31K | -1.59M | -195.70K | -485.44K | -147.61K | -265.64K | -644.31K | -907.56K | -202.54K | -710.89K | -350.24K | -94.26K | -907.44K | -698.60K | -6.19M | -2.88M | -4.04M | -1.24M | -538.87K | -1.46M | -1.70M | -902.11K | -651.48K | -1.28M | -494.30K | -1.20M | -1.18M | -1.77M | -883.82K | -1.24M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.23 | - | - | -7.73 | - | - | -2.00 | -43.48 | - | -0.44 | -0.82 | - | - |
| R&D Expense | 23.40K | 0 | - | 96.00K | 323.00K | 0 | 0 | 0 | 8.66K | - | 32.79K | 0 | - | 0 | 0 | - | - | 0 | - | 0 | 15.20K | 0 | 0 | 0 | 166.79K | 191.76K | 222.47K | 361.65K | 45.94K | 362.50K | 432.93K | 368.56K | 238.01K | 222.03K | 436.24K | 126.36K | 215.28K | 196.23K | 119.30K | 31.72K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 1.71K | 0 | 0 | 0 | 21.12K | 71.41K | 228.43K | 4.35M | 24.09M | 34.87M | 36.31M |
| Gross Profit | - | - | - | - | - | - | - | 0 | 0 | 10.07K | 45.56K | 110.60K | 1.70M | 8.34M | 10.67M | 12.26M |
| Operating Income | - | -556.20K | -706.68K | -1.94M | -1.76M | -780.28K | -993.11K | -857.19K | -1.16M | -641.64K | -576.87K | -2.44M | -27.00M | -4.79M | -5.81M | -6.23M |
| Net Income | -537.38K | -556.20K | -707.95K | -2.49M | -1.93M | -1.65M | -3.50M | -1.04M | -2.16M | -1.66M | -2.78M | -12.44M | -26.74M | -4.51M | -5.13M | -5.98M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -4.76 | -1.76 | -351.36 | -7.32 | - |
| R&D Expense | 0 | 142.65K | 1.83K | 137.40K | 327.00K | 8.66K | 32.79K | 0 | 12.80K | 15.20K | 1.73K | 672.21K | 811.86K | 1.86M | 933.90K | 604.31K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Aug 2009 | Sep 2009 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 207.62K | 106.44K | 134.79K | 31.24K | 143.42K | 673.26K | 64.40K | 257.49K | 1.15M | 98.14K | 1.05M | 2.20M | 29.24M | 27.35M | 30.56M | 30.08M |
| Total Equity | 0 | 336.11K | 97.80K | 196.22K | 103.00K | 70.43K | -7.71K | -387.58K | -597.04K | -209.70K | -573.36K | -55.75K | -735.38K | -954.84K | 211.66K | 21.63M | 21.21M | 23.50M | 23.04M |
| Cash & Equivalents | - | - | - | 162.39K | 60.69K | 132.64K | 31.24K | 143.42K | 50.80K | 57.45K | 107.53K | 110.53K | 40.50K | 989.89K | 2.05M | 21.83M | - | - | - |
| Total Liabilities | - | - | - | 11.40K | 3.43K | 64.37K | 38.95K | 531.00K | 1.27M | 274.10K | 830.85K | 1.20M | 833.53K | 2.00M | 1.99M | 7.62M | 6.14M | 7.06M | 7.04M |
| Current Liabilities | - | - | - | - | - | - | - | 531.00K | 1.27M | 274.10K | 751.14K | 912.48K | 833.53K | 1.05M | 91.23K | 6.93M | 5.55M | 6.31M | 6.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -348.32K | -297.30K | -393.05K | -564.40K | -538.60K | -867.64K | -314.18K | -543.52K | -512.81K | -495.80K | -657.30K | -1.83M | -5.25M | -8.78M | -12.52M | -5.33M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | -623.60K | -3.44K | -84.01K | -13.91K | -15.28K | -1.19K | 0 | -14.62M | -656.15K | -1.98M | -836.31K |
| Financing Cash Flow | 398.60K | 195.60K | 465.00K | 463.00K | 650.78K | 1.40M | 324.62K | 670.71K | 527.64K | 442.25K | 1.61M | 2.90M | 39.47M | 3.43M | 8.94M | 4.75M |
| Capital Expenditure | - | - | - | - | -0 | -4.79K | -3.44K | -3.72K | -18.85K | -860 | -1.19K | -0 | -193.98K | -82.25K | -1.66M | -174.49K |
| Free Cash Flow | - | - | - | - | -538.60K | -872.44K | -317.62K | -547.24K | -531.66K | -496.66K | -658.49K | -1.83M | -5.44M | -8.86M | -14.18M | -5.51M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | - | 541.14K | 3.14M | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | 47.7% | 63.8% | 48.4% | 39.0% | 34.6% | 30.6% | 33.8% |
| Operating Margin % | - | - | - | - | - | -45,683.7% | - | - | - | -3,037.9% | -807.8% | -1,068.2% | -621.3% | -19.9% | -16.7% | -17.2% |
| Net Margin % | - | - | - | - | - | -96,774.5% | - | - | - | -7,860.9% | -3,898.7% | -5,444.4% | -615.4% | -18.7% | -14.7% | -16.5% |
| ROE % | -273.9% | -540.0% | -1,005.2% | 32,315.0% | 499.0% | 276.8% | 1,667.5% | 181.4% | 3,867.3% | 225.8% | 291.6% | -5,875.6% | -123.7% | -21.2% | -21.8% | -25.9% |
| ROCE % | - | - | - | - | 452.8% | 130.7% | 473.6% | 173.6% | -497.4% | 87.3% | 9,893.2% | -115.6% | -121.0% | -22.0% | -24.0% | -26.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SBFM
Sunshine Biopharma's 2mg Tablet for Endometriosis Pain Wins Canadian Approval - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQYVA5WEFXc3RGRTByYXo1Y194dks3RGN1bXZWby1PeXRWUUFWR2FrUUpsRFdPQnlCalJiSXpLNDZoYmZ4anliYkZmTEJ0aWQxWHNoYzFlVlFzcm1mTVEzaVEwUk55U3hPLWNtd0pXanlkVng1dUVONHlxZ2F3cXhKZkt2bGlESnc0aTZEQn…
SBFM Looks 84.2% Undervalued on GF Value™ Despite Distressed Fun - GuruFocus
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOV3lwMWJMZG5WXy1oQUdpT3cyV2NJTGdGSlQ3dHZ3aE44TlF6VjlTMklfYWxYM2ZJc1A2WHl5aFpoSC0tNVV1SnFrcGRTeWtmelgtV0UzeTF6dXRmN2xZZXdJTzhiTnRKVExVbVBrejZrMG5LWlQ4UzRsRW5nR1ltYlIybkg1X2NYWUNoM3…
Why Sunshine Biopharma (SBFM) Stock Dropped After Hours Today - Benzinga
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNdHBKajJfeTdpNmh1U0VnQVpDdDVEQmxZTTlQb0hQTFBpTE9xd2E4UDVVeTNkd0VFc05VRW15U2hpNXR5NHZmSFVyclJvQnB0emE1bS01eGpxYVBuSEtRSjl6X3NSaWRSQWZZNG40T1U0Yjl6T1VWOTcyTEI3OU00UnBkcmUwRnpQSFM3ZW…
SBFM Stock Jumps As Sunshine Biopharma Secures New Drug Approvals - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxNVWtCM3ItbnFmeERQUkVHNHpTSnZMQy1lN1FoQWNYbUZGS0NDei1IdFlyR3E1WkRHVTdkSmdMS1FhTEdiYmxHR0swZnJFZ3BTQVEyRzg4TzNNcW8xd0tWSEtkM2FGNXN1ZUZpSm5qZnllMHltYmVhT0FuNHRzNm1tUQ?oc=5" target="_…
Sunshine Biopharma (SBFM) rockets higher as traders focus on low-float dynamics after recent SEC financing filings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxQUXBrdGlXWGc0b3ZLUzVqSjhCWGZ5cmxhZE04SGVwM29fcmxOTGhNUGphQVhzQVhMWjd6RlhGT2QxdU9mbEtydHBXcXJBWVVndHVlUXVWQmY5bG9BOENUWW5NalVDMjdsRU9CcUNGRkVKV2tSZS00RjNSZVRFSWdDQWpuSF8tS3FfWEQxRD…
SBFM Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFB4WWtMYUV0WVZfem52VzZZaWpDTG5ySUtVVnpfekQ4WVIxREdmdm91REV6cDZEaUNySU51STJfRlluLVF0YldnVE1vNDRjeXl0cUlxaG5WN3hJelljUmlCMlBGWDRjZjhwWWtycDQ4SEZtcnNNZmx4bkNn?oc=5" target="_blank">SBF…
SBFM — Frequently Asked Questions
What is the current share price of SBFM?
As of 2026-08-05 17:25 PDT, SBFM trades at $1.33 on NASDAQ/NYSE. Its 52-week range is $1.17 to $22.00.
What is the P/E ratio of SBFM?
SBFM trades at a trailing price-to-earnings (P/E) ratio of -0.18.
What is the return on equity (ROE) of SBFM?
SBFM has a return on equity (ROE) of -25.94%. Its return on capital employed (ROCE) is -26.35%.
Is SBFM a good stock to buy?
This page provides a data-driven analysis of SBFM, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.